INNATE PHARMA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.07.22	Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
21.07.22	Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development (Businesswire)
23.06.22	Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
03.06.22	Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer (Businesswire)
20.05.22	Outcome of Innate Pharma’s 2022 Annual General Meeting (Businesswire)
11.05.22	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
10.05.22	Innate Pharma Reports First Quarter 2022 Financial Results and Business Update (Businesswire)
10.05.22	Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022 (Businesswire)
03.05.22	Innate Pharma Establishes an At-The-Market ("ATM”) Program on Nasdaq (Businesswire)
03.05.22	Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update (Businesswire)
29.04.22	Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca (Businesswire)
08.04.22	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022 (Businesswire)
05.04.22	Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F (Businesswire)
24.03.22	Innate Pharma Reports Full Year 2021 Financial Results and Business Update (Businesswire)
17.03.22	Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results (Businesswire)
03.03.22	Number of Shares and Voting Rights of Innate Pharma as of March 1, 2022 (Businesswire)
15.02.22	Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022 (Businesswire)
04.02.22	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
24.01.22	Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022 (Businesswire)
05.01.22	Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans (Businesswire)
04.01.22	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
16.12.21	Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers (Businesswire)
09.12.21	Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress (Businesswire)
02.12.21	Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress (Businesswire)
24.11.21	Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference (Businesswire)
21.10.19	Innate Pharma Announces Closing of Global Offering (GlobeNewswire)
18.10.19	Innate Pharma announces the exercise in full of the option granted to the underwriters of its global offering and Nasdaq global select market listing to purchase 1,875,000 additional ADSs (GlobeNewswire)
17.10.19	Innate Pharma announces trading halt of its ordinary shares on Euronext Paris (GlobeNewswire)
17.10.19	Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market (GlobeNewswire)
07.10.19	Innate Pharma announces launch of proposed global offering and Nasdaq listing (GlobeNewswire)
20.09.19	Innate Pharma files registration statement for proposed initial public offering in the United States (GlobeNewswire)
12.06.19	Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML (GlobeNewswire)
31.05.19	Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs) (GlobeNewswire)
29.01.19	INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME (GlobeNewswire)
23.10.18	AstraZeneca beteiligt sich an französischer INNATE PHARMA (Dow Jones) Der Pharmariese Astrazeneca erweitert seine Kooperation mit INNATE PHARMA und erwirbt zudem eine Beteiligung an dem französischen Biotechunternehmen.» mehr
23.10.18	Britain's AstraZeneca to buy 9.8 percent stake in France's Innate Pharma (Reuters)
09.10.16	Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress (Businesswire)
09.10.16	Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu INNATE PHARMA SA

Aktien Top/Flop

Meistgelesene Nachrichten